Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vivo engineering tumor cells to a universal "all-in-one" cancer vaccine with full antigen spectrum.

Science advances·2026
Same author

Carotid plaque formation prediction model and validation: a case-control study.

Frontiers in cardiovascular medicine·2026
Same author

IL-12 augments adoptive cell therapy by reshaping CD8<sup>+</sup> T dynamics and broadening antitumor immunity.

Cancer letters·2026
Same author

Electroactive interface-enhanced dielectric elastomer with ultrahigh electroadhesion and multifunctional droplet actuation.

Science advances·2026
Same author

Lacylation of Stearoyl-CoA Desaturase-1 Contributes to the Myocardial Ischemia-Reperfusion Injury Through Regulating Wnt/β-Catenin Signaling.

Journal of cardiovascular translational research·2026
Same author

Exploring the application of generative artificial intelligence in nursing: a cross-sectional study.

Frontiers in public health·2026

Related Experiment Video

Updated: Sep 2, 2025

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

6.9K

Drug development progress in duchenne muscular dystrophy.

Jiexin Deng1, Junshi Zhang2, Keli Shi3

  • 1School of Nursing and Health, Henan University, Kaifeng, China.

Frontiers in Pharmacology
|August 8, 2022
PubMed
Summary

Duchenne muscular dystrophy (DMD) is a severe genetic disorder. Current research focuses on novel therapies and predictive modeling to improve patient outcomes and guide drug development for this incurable condition.

Keywords:
clinical trialdrug developementduchenne muscular dystrophy (DMD)research and developmenttherapeutic strategies

More Related Videos

Assessing Functional Performance in the Mdx Mouse Model
10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

32.7K
Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.1K

Related Experiment Videos

Last Updated: Sep 2, 2025

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

6.9K
Assessing Functional Performance in the Mdx Mouse Model
10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

32.7K
Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.1K

Area of Science:

  • Neurology
  • Genetics
  • Pharmacology

Background:

  • Duchenne muscular dystrophy (DMD) is a severe, progressive, X-linked genetic disorder.
  • Caused by mutations in the dystrophin gene, leading to a lack of functional dystrophin protein.
  • This deficiency results in chronic muscle fiber damage, muscle deterioration, and reduced quality of life.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for DMD.
  • To provide insights into drug development pathways, including approved drugs and candidates.
  • To summarize trial endpoints and enrollment data for DMD clinical studies.

Main Methods:

  • Review of approved drugs and drug candidates in DMD development.
  • Analysis of therapeutic strategies targeting dystrophin deficiency and secondary pathology.
  • Examination of longitudinal modeling for predictive purposes in drug development.

Main Results:

  • Overview of various therapeutic approaches, including gene replacement, exon skipping, and readthrough therapy.
  • Identification of strategies addressing secondary DMD pathologies like inflammation and myostatin.
  • Characterization of MRI and functional endpoints for predictive modeling in clinical trials.

Conclusions:

  • While no cure exists, improved care and novel therapies can delay DMD progression and enhance life expectancy.
  • Ongoing research into gene-targeted and secondary pathology treatments offers hope for DMD patients.
  • Predictive modeling aids in informing critical decisions within the DMD drug development pipeline.